⟵ Back to Search Results

BGB-900-103

Active, not recruiting

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

Beigene Study ID info

BGB-900-103

ClinicalTrials.gov ID info

NCT03666143

China Drug Trials ID info

CTR20181404

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents